News
The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...
Regeneron Pharmaceuticals ( NASDAQ: REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...
Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...
Stocktwits on MSN16h
Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions
Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended ...
TipRanks on MSN17h
Regeneron says FDA delayed review of two Eylea HD submissions
Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...
The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback